1. Home
  2. SNDX vs RDW Comparison

SNDX vs RDW Comparison

Compare SNDX & RDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • RDW
  • Stock Information
  • Founded
  • SNDX 2005
  • RDW 2020
  • Country
  • SNDX United States
  • RDW United States
  • Employees
  • SNDX N/A
  • RDW N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • RDW Military/Government/Technical
  • Sector
  • SNDX Health Care
  • RDW Industrials
  • Exchange
  • SNDX Nasdaq
  • RDW Nasdaq
  • Market Cap
  • SNDX 1.1B
  • RDW 1.2B
  • IPO Year
  • SNDX 2016
  • RDW N/A
  • Fundamental
  • Price
  • SNDX $14.75
  • RDW $7.85
  • Analyst Decision
  • SNDX Strong Buy
  • RDW Buy
  • Analyst Count
  • SNDX 10
  • RDW 8
  • Target Price
  • SNDX $38.40
  • RDW $16.56
  • AVG Volume (30 Days)
  • SNDX 2.0M
  • RDW 3.9M
  • Earning Date
  • SNDX 11-04-2025
  • RDW 11-05-2025
  • Dividend Yield
  • SNDX N/A
  • RDW N/A
  • EPS Growth
  • SNDX N/A
  • RDW N/A
  • EPS
  • SNDX N/A
  • RDW N/A
  • Revenue
  • SNDX $77,933,000.00
  • RDW $261,353,000.00
  • Revenue This Year
  • SNDX $585.73
  • RDW $34.83
  • Revenue Next Year
  • SNDX $94.17
  • RDW $41.86
  • P/E Ratio
  • SNDX N/A
  • RDW N/A
  • Revenue Growth
  • SNDX 2126.66
  • RDW N/A
  • 52 Week Low
  • SNDX $8.58
  • RDW $6.22
  • 52 Week High
  • SNDX $22.50
  • RDW $26.66
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 47.48
  • RDW 33.32
  • Support Level
  • SNDX $15.71
  • RDW $8.08
  • Resistance Level
  • SNDX $16.50
  • RDW $9.60
  • Average True Range (ATR)
  • SNDX 0.81
  • RDW 0.46
  • MACD
  • SNDX -0.36
  • RDW 0.22
  • Stochastic Oscillator
  • SNDX 2.73
  • RDW 4.28

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About RDW Redwire Corporation

Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's plan enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.

Share on Social Networks: